Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease P

Barnor, Jacob Samson; Endo, Yumihiko; Habu, Yuichiro; Miyano-Kurosaki, Naoko; Kitano, Michiko; Yamamoto, Hisako; Takaku, Hiroshi

doi:10.1016/j.bmcl.2004.07.021

Cited by 11 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 COS cells co-transfected with an expressed RNAse P EGS either against a site in HIV-1 tat or the 5 0 -UTR along with a pNL4-3 luc construct reduced viral output in a single-round co-transfection assay. 32 In a follow-up study, a combination of RNAse P and RNAse Z L EGS were more efficient at reducing HIV-1 replication than EGS alone. 33 The efficacy of these anti-HIV EGS in long-term infectious assays awaits assessment.…”

Section: Ribozymes and Aptamers Continue To Evolve As Therapeuticsmentioning

confidence: 99%

Progress and prospects: RNA-based therapies for treatment of HIV infection

2007

View full text Add to dashboard Cite

The current treatment regimen for HIV-infected individuals combines two or more drugs targeting different viral proteins such as RT and gag. Resistance to conventional drugs can develop quickly, and typically persists. The prospect of longer, continuous antiretroviral therapy brings with it the need for new antiretroviral drugs and approaches. In this context, gene therapies have the potential to prolong life and quality of life as an additional therapeutic class and may serve as an adjuvant to traditional treatments. This review focuses on RNA-based hematopoietic cell gene therapy for treatment of HIV infection. Recent advances in our understanding of RNA interference (RNAi) make this an especially attractive candidate for anti-HIV gene therapy although ribozyme and RNA decoy/aptamer approaches can be combined with RNAi to make a combinatorial therapy akin to highly active anti-retroviral therapy.

show abstract

Section: Ribozymes and Aptamers Continue To Evolve As Therapeuticsmentioning

confidence: 99%

Progress and prospects: RNA-based therapies for treatment of HIV infection

2007

View full text Add to dashboard Cite

show abstract

“…[18] The short EGS, 12 nucleotides long, was designed to hybridize as an sEGS to a region of the viral RNA with the expected cleavage site located 5 to the double stranded region ( Figure 1B). The greatest inhibitory effect on HIV-1 replication was detected with the sEGS (sEGS-tat) vector as the target of the HIV-1 tat gene ( Figures 1A and B).…”

Section: Design and Construction Of The U6-egs Driven Expression Systemmentioning

confidence: 99%

“…These vectors have been previously described with a high cleavage affinity. [18,23] Furthermore, the control vector designs were constructed to express pSV2neo-U6-mutant-EGS expression vectors (U6-mvif-sEGS, U6-mtat-sEGS, and U6-mvif-mtat-sEGS) ( Figure 2). …”

Section: Design and Construction Of The U6-egs Driven Expression Systemmentioning

confidence: 99%

“…[14,15] RNA-based EGSs have been expressed endogenously as transgenes in both bacteria and mammalian cells, [14,16] and have been effective in inhibiting gene expression by HIV-1. [17,18] Mammalian cells contain the essential enzyme, tRNA 3 -processing endoribonuclease (tRNase Z or 3 -tRNase; EC 3.1.26.11), which removes 3 trailers from pre-tRNAs. [19] The long-form enzyme (tRNase ZL) is unique in that it can cleave any RNA at any site when directed by a small-guide RNA (sgRNA) in vitro.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Suppression of HIV-1 Replication by a Combination of Endonucleolytic Ribozymes (RNase P and tRNase ZL)

Ikeda

Habu

Miyano-Kurosaki

et al. 2006

Nucleosides, Nucleotides and Nucleic Acids

Self Cite

View full text Add to dashboard Cite

We examined the combinatorial action of RNase P and tRNase ZL-mediated specific inhibition of HIV-1 in cultured cells. We designed two short extra guide sequences (sEGS) that specifically recognize the tat and vifregions of HIV-1 mRNA and mediate the subsequent cleavage of hybridized mRNA by the RNase P and tRNase ZL components. We constructed an RNase P and tRNase ZL-associated vif and tat sEGS expression vector; which used the RNA-polymerase III dependent U6 promoter, as an expression cassette for EGS. Together, the RNase P and tRNase ZL-associated sEGS molecules allow more efficient suppression of HIV-1 mRNA production when separately applied. The possibilities offered by the vector to encode sEGS will provide a powerful tool for gene therapy.

show abstract

“…RNaseP subunits (Kovrigina et al 2003;Zhang et al 2004), protein kinase C-a , as well as Human Immunodeficiency Virus-1 (HIV-1) mRNA (Kraus et al 2002;Barnor et al 2004) are some examples of transcripts that have been successfully silenced using RNaseP-EGS technology . Some advantages to the use of RNaseP-EGS include the ability to chemically modify the molecule based on experience acquired through the use of DNA antisense oligonucleotides, the fact that it uses a well defined degradation pathway and that the 3' end of a known G residue is cleaved within the target transcript.…”

Section: Rnase P Associated External Guide Sequencesmentioning

confidence: 99%

Assessing the role of Syntaxin18 in controlling c-myc mRNA expression and growth in human breast cancer cells.

Bassett¹

View full text Add to dashboard Cite

Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease P

Cited by 11 publications

References 23 publications

Progress and prospects: RNA-based therapies for treatment of HIV infection

Progress and prospects: RNA-based therapies for treatment of HIV infection

Suppression of HIV-1 Replication by a Combination of Endonucleolytic Ribozymes (RNase P and tRNase ZL)

Assessing the role of Syntaxin18 in controlling c-myc mRNA expression and growth in human breast cancer cells.

Contact Info

Product

Resources

About